

Bacterial Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/BCC7B2BF1CAAEN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: BCC7B2BF1CAAEN

Abstracts

The 7 major bacterial conjunctivitis markets reached a value of US\$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 4.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.23% during 2024-2034.

The bacterial conjunctivitis market has been comprehensively analyzed in IMARC's new report titled "Bacterial Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bacterial conjunctivitis, commonly called pink eye, refers to an infectious ophthalmic condition caused by various bacteria, primarily staphylococci and streptococci. It is characterized by inflammation of the conjunctiva, the thin, transparent layer covering the white part of the eye and the inner region of the eyelids. The symptoms of the ailment include excessive tearing, redness, itching, a gritty feeling in the eye, and a discharge that can be watery or thick and yellow-green in color. The eye may appear pink or red due to the enlargement of blood vessels in the conjunctiva. Additionally, the eyelids can become stuck together, especially upon waking, due to the dried discharge. The diagnosis of bacterial conjunctivitis typically involves a thorough eye examination by a healthcare professional. They will assess the symptoms, evaluate the eye using a slit lamp microscope, and may collect a sample of the eye discharge for laboratory analysis. This investigation can help to identify the specific bacteria causing the infection.

The rising prevalence of eye disorders caused by the infiltration of harmful bacteria into the conjunctiva is primarily driving the bacterial conjunctivitis market. In addition to this, the inflating utilization of effective treatments, including antibiotic eye drops or ointments and, in severe cases, oral antibiotics, to alleviate the condition and curtail its progression, is also creating a positive outlook for the market. Moreover, the

widespread adoption of hygiene and preventive measures, given their role in averting bacterial transmission and reducing the likelihood of conjunctival infections, is further bolstering the market growth. Apart from this, the increasing usage of warm compresses and gentle cleansing techniques as complementary strategies, aiding in the reduction of discomfort and irritation as well as expediting recovery from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of lubricating artificial tears that help to alleviate symptoms and maintain ocular moisture in individuals suffering from this ailment is also augmenting the market growth. Furthermore, the escalating application of probiotic-based interventions, since they are designed to restore a healthy ocular microbiome and enhance the eye's natural defense mechanisms against bacteria, is expected to drive the bacterial conjunctivitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the bacterial conjunctivitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bacterial conjunctivitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bacterial conjunctivitis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bacterial conjunctivitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bacterial conjunctivitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bacterial conjunctivitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the bacterial conjunctivitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the bacterial conjunctivitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the bacterial conjunctivitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of bacterial conjunctivitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of bacterial conjunctivitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of bacterial conjunctivitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with bacterial conjunctivitis across the seven major markets?

What is the size of the bacterial conjunctivitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of bacterial conjunctivitis?

What will be the growth rate of patients across the seven major markets?

Bacterial Conjunctivitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for bacterial conjunctivitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the bacterial conjunctivitis market?

What are the key regulatory events related to the bacterial conjunctivitis market?

What is the structure of clinical trial landscape by status related to the bacterial conjunctivitis market?

What is the structure of clinical trial landscape by phase related to the bacterial conjunctivitis market?

What is the structure of clinical trial landscape by route of administration related to the bacterial conjunctivitis market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 BACTERIAL CONJUNCTIVITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 BACTERIAL CONJUNCTIVITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 BACTERIAL CONJUNCTIVITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 BACTERIAL CONJUNCTIVITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 BACTERIAL CONJUNCTIVITIS - UNMET NEEDS

10 BACTERIAL CONJUNCTIVITIS - KEY ENDPOINTS OF TREATMENT

11 BACTERIAL CONJUNCTIVITIS - MARKETED PRODUCTS

- 11.1 List of Bacterial Conjunctivitis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Azasite (Azithromycin Ophthalmic Solution) - Merck & Co.
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Ocuflax (Ofloxacin Ophthalmic Solution) - Allergan
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Zymaxid (Gatifloxacin Ophthalmic Solution) - Allergan
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Verkazia (Cyclosporine Ophthalmic Emulsion) - Silver Spring
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Vigamox (Moxifloxacin Ophthalmic Solution) - Novartis
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 BACTERIAL CONJUNCTIVITIS - PIPELINE DRUGS

- 12.1 List of Bacterial Conjunctivitis Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 IVIEW-1201 - IVIEW Therapeutics
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. BACTERIAL CONJUNCTIVITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. BACTERIAL CONJUNCTIVITIS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 BACTERIAL CONJUNCTIVITIS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Bacterial Conjunctivitis - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Bacterial Conjunctivitis - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Bacterial Conjunctivitis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Bacterial Conjunctivitis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Bacterial Conjunctivitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Bacterial Conjunctivitis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Bacterial Conjunctivitis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Bacterial Conjunctivitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Bacterial Conjunctivitis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Bacterial Conjunctivitis - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Bacterial Conjunctivitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Bacterial Conjunctivitis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Bacterial Conjunctivitis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Bacterial Conjunctivitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Bacterial Conjunctivitis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Bacterial Conjunctivitis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Bacterial Conjunctivitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Bacterial Conjunctivitis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Bacterial Conjunctivitis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Bacterial Conjunctivitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Bacterial Conjunctivitis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Bacterial Conjunctivitis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Bacterial Conjunctivitis - Access and Reimbursement Overview

16 BACTERIAL CONJUNCTIVITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 BACTERIAL CONJUNCTIVITIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 BACTERIAL CONJUNCTIVITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Bacterial Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/BCC7B2BF1CAAEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BCC7B2BF1CAAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

